Zimmer Biomet (ZBH) PT Raised to $155.00

Zimmer Biomet (NYSE:ZBH) had its target price hoisted by equities researchers at Needham & Company LLC from $144.00 to $155.00 in a research note issued on Tuesday. The firm currently has a “strong-buy” rating on the medical equipment provider’s stock. Needham & Company LLC’s price target would indicate a potential upside of 22.53% from the stock’s current price.

A number of other analysts also recently weighed in on the stock. SunTrust Banks increased their price target on shares of Zimmer Biomet to $142.00 and gave the company a “buy” rating in a report on Monday. Morgan Stanley increased their price target on shares of Zimmer Biomet from $140.00 to $150.00 in a report on Monday. ValuEngine raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Thursday, January 11th. Canaccord Genuity reissued a “hold” rating and issued a $132.00 price target on shares of Zimmer Biomet in a report on Friday, January 5th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Zimmer Biomet in a research note on Friday, January 5th. Two analysts have rated the stock with a sell rating, five have given a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $138.58.

Shares of Zimmer Biomet (ZBH) traded down $0.89 during trading on Tuesday, reaching $126.50. 1,829,364 shares of the company’s stock were exchanged, compared to its average volume of 1,425,945. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88. Zimmer Biomet has a 12-month low of $108.03 and a 12-month high of $133.49. The company has a market cap of $25,558.18, a P/E ratio of 39.78, a PEG ratio of 1.97 and a beta of 1.15.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.10. Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. The firm had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.03 billion. During the same period in the prior year, the firm earned $2.14 EPS. The business’s revenue was up 3.0% on a year-over-year basis. analysts forecast that Zimmer Biomet will post 8.03 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in the stock. Parkside Financial Bank & Trust increased its position in Zimmer Biomet by 0.5% in the 3rd quarter. Parkside Financial Bank & Trust now owns 964 shares of the medical equipment provider’s stock valued at $125,000 after acquiring an additional 5 shares in the last quarter. IFP Advisors Inc boosted its stake in shares of Zimmer Biomet by 0.5% in the 2nd quarter. IFP Advisors Inc now owns 1,507 shares of the medical equipment provider’s stock valued at $181,000 after purchasing an additional 8 shares during the last quarter. Enterprise Financial Services Corp boosted its stake in shares of Zimmer Biomet by 0.3% in the 2nd quarter. Enterprise Financial Services Corp now owns 2,646 shares of the medical equipment provider’s stock valued at $340,000 after purchasing an additional 9 shares during the last quarter. Cypress Wealth Advisors LLC boosted its stake in shares of Zimmer Biomet by 0.4% in the 2nd quarter. Cypress Wealth Advisors LLC now owns 3,081 shares of the medical equipment provider’s stock valued at $371,000 after purchasing an additional 11 shares during the last quarter. Finally, Park Avenue Institutional Advisers LLC boosted its stake in shares of Zimmer Biomet by 1.2% in the 1st quarter. Park Avenue Institutional Advisers LLC now owns 1,128 shares of the medical equipment provider’s stock valued at $120,000 after purchasing an additional 13 shares during the last quarter. Institutional investors and hedge funds own 86.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Zimmer Biomet (ZBH) PT Raised to $155.00” was originally reported by American Banking and Market News and is the sole property of of American Banking and Market News. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/01/30/zimmer-biomet-zbh-pt-raised-to-155-00.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)